TG Therapeutics $TGTX slumped amid increased trading volume after it announced that it has filed a request with the FDA to amend the protocol in its Phase 3 clinical trial, GENUINE, evaluating lead product candidate TG-1101 in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL). The altered protocol, if approved, will drop progression-free survival (PFS) as an efficacy endpoint (Part II of the study) with overall response rate (ORR) serving as the sole primary endpoint (Part I). Enrollment in the revised trial should be finalized this quarter with top-line data likely in H1 2017.